CELZ Stock Analysis
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)
Key Findings Summary
CELZ is a micro-cap commercial-stage regenerative medicine biotech company with negligible revenue, ongoing clinical trials in back pain, diabetes, and other indications, heavy reliance on dilutive financings, and extremely volatile stock performance driven by news flow and warrant exercises.
Data primarily sourced from Yahoo Finance, company press releases, and SEC filings as of early August 2026.
Company Overview & History
Overview (Fact)
- Commercial-stage biotechnology company focused on novel biological therapeutics using stem cell and regenerative approaches in immunotherapy, endocrinology, urology, neurology, and orthopedics.
- Headquartered in Phoenix, Arizona; founded December 3, 1998 by Timothy Warbington (current CEO).
- Small team: 4 full-time employees (Fact from Yahoo Finance profile).
- Commercial products: CaverStem (erectile dysfunction), FemCelz (female sexual function).
- Pipeline includes AlloStem/CELZ-201 (allogeneic perinatal cells) for chronic lower back pain (ADAPT trial, Phase 2/advancing to Phase 3 planning), type 1 diabetes (CREATE-1), ImmCelz (personalized immune therapy), StemSpine, OvaStem, and others; recent expansion into exosome-based therapies and Project PHOENIX (AI-driven registry for U.S. veterans' burn pit exposure).
- Over 60 pending or issued patents (company website).
History (Fact)
- Long operating history with multiple name changes and reverse stock splits (e.g., 1:10 in 2023).
- Stock has experienced extreme volatility and dilution through warrant exercises and equity offerings.
- Recent milestones: Multiple FDA clearances/expansions for trials, WHO INN approval for "olastrocel", positive interim data on back pain and knee OA programs, Orphan Drug Designation for ImmCelz.
Company Website | Yahoo Profile
Data Limitation: Historical details rely on company disclosures and third-party summaries; full corporate history may involve prior reverse mergers or restructurings common in micro-cap biotechs.
Stock Performance & Company Financials
Stock Performance (Fact)
- Highly volatile penny stock with 52-week range of approximately $0.62 – $6.25.
- YTD return ~+30%; 1-year ~+61%; longer-term returns positive but with massive drawdowns from historical highs (e.g., all-time closing high of ~487,500 in 2016 prior to splits).
- Beta ~1.94 (high volatility relative to market).
- Frequent large single-day moves tied to press releases, financings, and trial updates; average daily volume varies widely (millions of shares on active days).
Yahoo Finance Historical Data | Macrotrends 11-Year History
Financial Highlights (Fact – TTM / Recent Periods)
| Metric |
Value |
Notes |
| Revenue (TTM) |
$3,000 |
Negligible; prior year ~$6,000–$11,000 annually |
| Net Income (TTM) |
-$5.76 million |
Consistent annual losses ~$5–10M |
| EPS (TTM) |
-$2.07 |
Diluted |
| Cash & Equivalents (mrq) |
~$5.85 million |
Positive working capital; funded via warrant exercises |
| Total Debt |
Minimal (~$14k) |
Low leverage |
| Operating Cash Flow (TTM) |
-$5.59 million |
Burn rate typical for clinical-stage biotech |
| Market Cap Range (recent) |
$3M – $9M |
Fluctuates with share price and issuances |
Yahoo Financials | Yahoo Key Statistics
Interpretation & Uncertainties: Extremely low revenue indicates primarily pre-commercial or minimal commercial sales. Losses reflect R&D and G&A spending on clinical programs. Frequent equity raises (warrant exercises providing $3–4.5M proceeds in recent instances) suggest ongoing dilution risk. Financials are TTM/mrq as reported; actual burn rate and runway depend on future financings and trial progress. No dividends.
Analyst Ratings
Consensus & Targets (Fact from Multiple Sources)
- Limited coverage (typically 1–7 analysts noted across platforms).
- Some reports cite "Buy" or "Strong Buy" with average price target of $20.00 (Roth MKM cited in news; implies substantial upside from current levels).
- Other aggregators (e.g., MarketBeat) report "Reduce" consensus based on 1 Hold + 1 Sell rating.
- Recent actions: Buy rating from Roth MKM (July 2026); positive commentary on knee data and trial expansions.
Rating Comparison Table
| Source |
Consensus |
Target |
| Yahoo Finance |
Strong Buy (1 analyst) |
$20.00 |
| MarketBeat |
Reduce |
N/A |
| MarketWatch / Others |
Buy (limited) |
$20.00 |
Interpretation & Uncertainties: Analyst coverage is sparse and conflicting—high targets from bullish voices contrast with "Reduce" ratings elsewhere. Targets like $20 appear highly speculative for a micro-cap with minimal revenue. Ratings can change rapidly with news; investors should verify latest reports. Data limitation: Small number of analysts leads to low reliability of consensus.
Yahoo Analyst Estimates | MarketWatch Estimates
Customers & Competitors
Customers (Fact)
- Commercial products (CaverStem, FemCelz) target patients/clinics for erectile dysfunction and female sexual health; limited public disclosure of specific large customers or revenue sources.
- Clinical programs serve patients in trials (e.g., chronic lower back pain, diabetes, knee OA, veterans via Project PHOENIX).
- No major enterprise or pharmaceutical partner customers prominently disclosed; focus appears on direct or small-scale commercialization and research collaborations.
Interpretation: Revenue is minimal, suggesting early-stage commercialization or limited market penetration to date.
Competitors (Fact – Selected Small-Cap Biotechs)
| Company |
Ticker |
Market Cap (approx.) |
Focus |
| Azitra |
AZTR |
~$2M |
Skin microbiome / regenerative |
| Soligenix |
SNGX |
~$6M |
Biodefense, rare diseases |
| BioRestorative Therapies |
BRTX |
~$5–6M |
Stem cell therapies (back pain, etc.) |
| Others (e.g., Tempest, GT Biopharma) |
Various |
Small-cap range |
Immuno-oncology / regenerative |
Simply Wall St Competitors | MarketBeat Comparison
Uncertainty: Competitor list is illustrative of similarly sized regenerative/biotech peers; direct head-to-head competition is limited due to niche platforms. Customer details are sparse in public filings.
Recent News Highlights
- Project PHOENIX: AI-driven veteran burn pit exposure registry advancing (multiple 2026 releases).
- Clinical progress: ADAPT trial expansion/FDA clearance for back pain (CELZ-201/Olastrocel); positive knee OA data (93% response); diabetes and other programs.
- Financings: Multiple warrant exercise agreements generating $3–4.5M gross proceeds (2025–2026).
- IP/Regulatory: New patent allowances, WHO INN designation, Orphan Drug status.
- Other: Mid-year updates, shareholder letters, collaborations (e.g., Greenstone Biosciences).
Yahoo News | GlobeNewswire (company releases)
All information is for informational purposes only. Not investment advice. Verify latest data from primary sources as markets and filings change rapidly. Data limitations include reliance on aggregated third-party summaries, minimal analyst coverage, and the speculative nature of early-stage biotech development.